Key Panel Discussion at 3rd Oncology Partnering Conf. - July 7-8, 2014, Boston
Panel Discussion on "Innovative Partnering & Deal-making" Features Executives from Sanofi, Merck Serono, Johnson & Johnson, Novartis, AnaptysBio, and MedImmune at the 3rd Oncology Partnering & Deal-Making Conference (July 7-8, 2014 in Boston, MA).
- (1888PressRelease) April 06, 2014 - This panel discussion will cover topics including rationale-driving key deals of 2013 and continued trends into 2014 as well as aligning deal structures with corporate strategic goals and how the heightened risk environment is affecting deals. The pros and cons of regional deal-making will also be discussed. There are key questions to innovative partnering - at what stage or what type of data makes the asset most attractive to a buyer? How do you find and decide who a good partner is and what determines the value of the deal? What preparations should you make before the deal and what kind of terms besides the financials should you take into consideration? And perhaps most importantly, what are the criteria to attract investors? Come join this important and timely discussion.
Panel participants will include Anne Altmeyer, Vice President of Business Development and Licensing at Novartis; Varavani Dwarki, Vice President and Worldwide Head of Alliance Management Oncology and NCI Liaison at Sanofi; Catherine-Anne Pickering, Head of Oncology Licensing and Global Business Development at Merck Serono; Shakti Narayan, Senior Director of Transactions at Johnson & Johnson Innovation Center; Reginald Seeto, Head of Partnering and Strategy at MedImmune; Hamza Suria, President and Chief Executive Officer of AnaptysBio
GTCBio's 3rd Oncology Partnering & Deal Making Conference is a partnership and business development conference that provides an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the pharmaceutical industry. Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, partnership opportunities, alliance management, value maximization vs. capital efficiency, and the rebirth of IPOs. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum!
This conference is part of the larger Novel Cancer Therapeutics Summit, which consist of two co-located parallel conferences:
3rd Oncology Partnering & Deal-making Conference
5th Cancer Targets & Therapeutics Conference
For more information, please visit www.gtcbio.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam